- Home
- MNMD vs FISI Comparison
MNMD vs FISI Comparison
Compare MNMD & FISI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MNMD
- FISI
- Stock Information
- Founded
- MNMD 2019
- FISI 1817
- Country
- MNMD United States
- FISI United States
- Employees
- MNMD N/A
- FISI N/A
- Industry
- MNMD Pharmaceuticals and Biotechnology
- FISI Major Banks
- Sector
- MNMD Health Care
- FISI Finance
- Exchange
- MNMD Nasdaq
- FISI Nasdaq
- Market Cap
- MNMD 509.2M
- FISI 522.5M
- IPO Year
- MNMD N/A
- FISI 1999
- Fundamental
- Price
- MNMD $7.17
- FISI $27.42
- Analyst Decision
- MNMD Strong Buy
- FISI Buy
- Analyst Count
- MNMD 7
- FISI 3
- Target Price
- MNMD $26.29
- FISI $33.00
- AVG Volume (30 Days)
- MNMD 1.2M
- FISI 172.8K
- Earning Date
- MNMD 08-12-2025
- FISI 07-24-2025
- Dividend Yield
- MNMD N/A
- FISI 4.52%
- EPS Growth
- MNMD N/A
- FISI N/A
- EPS
- MNMD N/A
- FISI N/A
- Revenue
- MNMD N/A
- FISI $108,628,000.00
- Revenue This Year
- MNMD N/A
- FISI $101.16
- Revenue Next Year
- MNMD N/A
- FISI $6.68
- P/E Ratio
- MNMD N/A
- FISI N/A
- Revenue Growth
- MNMD N/A
- FISI N/A
- 52 Week Low
- MNMD $4.70
- FISI $18.56
- 52 Week High
- MNMD $10.44
- FISI $29.79
- Technical
- Relative Strength Index (RSI)
- MNMD 52.28
- FISI 66.18
- Support Level
- MNMD $6.40
- FISI $25.60
- Resistance Level
- MNMD $7.20
- FISI $26.16
- Average True Range (ATR)
- MNMD 0.43
- FISI 0.60
- MACD
- MNMD -0.03
- FISI 0.23
- Stochastic Oscillator
- MNMD 76.03
- FISI 95.56
About MNMD Mind Medicine (MindMed) Inc.
Mind Medicine Inc. is a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders. It is developing a pipeline of product candidates targeting neurotransmitter pathways that play key roles in brain health disorders. This includes explicitly pharmaceutically optimized product candidates derived from the psychedelic and empathogen drug classes, including MM120 and MM402, as its key product candidates. The MM120 is a proprietary, pharmaceutically optimized form of lysergide D-tartrate that is being developed to treat generalized anxiety disorder and clinical depressive disorder, and the MM402 is a proprietary form of the R-enantiomer of 3,4-methylenedioxymethamphetamine (MDMA), being developed to treat autism spectrum disorder (ASD).
About FISI Financial Institutions Inc.
Financial Institutions Inc operates as a financial holding company, engages in the provision of a wide range of consumer and commercial banking services to individuals, municipalities, and businesses in Western and Central New York. It operates through one segment: The Banking segment which includes all of the company's retail and commercial banking operations.